Improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy
- Conditions
- Drug AllergyNSAID-Induced Anaphylactoid ReactionAntibiotic Allergy
- Registration Number
- NCT03164044
- Lead Sponsor
- The Republican Research and Practical Center for Epidemiology and Microbiology
- Brief Summary
Current study evaluates the use of the improved Basophil Activation Test (BAT) in the diagnostics of IgE-mediated allergy to antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs).
- Detailed Description
Current study evaluates the use of the improved Basophil Activation Test (BAT) in the diagnostics of IgE-mediated allergy to antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs). Among commonly used CD63/CD203c markers, newly proposed molecules, such as CD69, CD107a, CD164, CD13, CD11b and CD300a will be assayed. Results obtained together with the other clinical data will be used to calculate sensitivity and specificity of the method.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 45
- suspected allergy to antibiotics or NSAIDs in the last 1 year.
- autoimmune diseases;
- HIV;
- hepatitis B/C;
- other acute or chronic infectious diseases;
- malignant neoplasms;
- leukemia;
- other severe acute or chronic intercurrent diseases;
- pregnancy/lactation;
- refuse of patient to participate in the trial.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sensitivity of the improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy 1 month Sensitivity of the improved Basophil Activation Test (BAT) in the diagnostics of allergy to antibiotics or NSAIDs
Specificity of the improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy 1 month Specificity of the improved Basophil Activation Test (BAT) in the diagnostics of allergy to antibiotics or NSAIDs
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Andrei Hancharou
🇧🇾Minsk, Belarus